Serum Institute of India will seek approval for a two full-dose regimen from the Indian drug regulator after its partner, Oxford University, cited data from early trials and said following
Trials in India over 1,600 people was done with two-full doses and the data has been submitted to the regulator
First Published: Dec 19 2020 | 0:22 AM IST
Key stories on business-standard.com are available only to BS Premium subscribers.
Register to read more on Business-Standard.com